BioSpace News Archive

iZafe Group iZafe Group AB announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021.

Piramal Pharma Limited unveiled its Sustainability Report FY21–22 to provide a view of its performance on Environment, Social, and Governance parameters.

SIFI S.p.A reported the presentation of positive results from the positive Phase 3 Study [NCT03274895] of AKANTIOR®, an investigational anti-amoebic polymer, an orphan drug, for the treatment of acanthamoeba keratitis.

4Moving Biotech announces that it has enrolled its first patient for phase I of LASARE clinical trial study.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the successful completion of a new production line for the medical radioisotope non-carrier-added lutetium-177 at its production facility IAZ in Garching near Munich.

A new whitepaper, released by the Wyss Center for Bio and Neuroengineering, reveals the first neural signals recorded by the ABILITY brain-computer interface system.

Immuron Limited is pleased to announce that it has signed a strategic investment and option agreement with Ateria Health Limited, a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome.

Kineta, Inc. announced that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research Special Conference: Tumor Immunology and Immunotherapy, to be held on October 21-24, 2022 as an in-person event in Boston, Massachusetts.

VectivBio Holding AG today announced positive interim data from the company’s ongoing Phase 2 STARS Nutrition study evaluating the safety, pharmacokinetics and efficacy of apraglutide, an investigational new drug that is a next-generation, long-acting synthetic GLP-2 agonist, in adult patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC).

Orthofix Medical Inc. today announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis or extremities.